Is the AI screening your resume biased? A lawsuit makes the case
Is the AI screening your resume biased? A lawsuit makes the case
Show Caption
Hide Caption
Pentagon blames AI for removal of webpages about historic figures
Pages about historic figures were taken down from the Pentagon's website amid a push to purge DEI. Officials say artificial intelligence is to blame.
A lawsuit against Workday alleges the company's screening technology discriminates against job applicants on the basis of race, age and disability in a case that raises new legal issues about how employers use artificial intelligence in hiring decisions.
Derek Mobley brought the discrimination lawsuit against the human resources software company in 2023, alleging he applied for hundreds of positions over seven years only to be repeatedly rejected.
Four other plaintiffs over the age of 40 have since joined the suit, blaming the AI recommendation technology that screens and ranks job applicants for 'disproportionately' preventing older workers from 'securing gainful employment.'
California federal judge Rita Lin ruled Friday the case can proceed as a collective action – similar to a class action – so Mobley can notify 'similarly situated individuals of the lawsuit and provide them an opportunity to opt in to having their claims heard on a collective basis.'
'We continue to believe this case is without merit,' Workday said in a statement. 'This is a preliminary, procedural ruling at an early stage of this case that relies on allegations, not evidence. The court has not made any substantive findings against Workday and has not ruled this case can go forward as a class action. We're confident that once Workday is permitted to defend itself with the facts, the plaintiff's claims will be dismissed.'
The Workday lawsuit raises new issues about the use of AI and shows the possible legal exposure for AI vendors and for employers that increasingly relying on it.
Human resources professionals lean heavily on AI technology to screen and rank applications and resumes. While the technology saves manpower and time, civil rights experts say the technology may have hidden biases that discriminate against job applicants based on protected characteristics such as gender and race.
'AI tools are trained with a large amount of data and make predictions about future outcomes based on correlations and patterns in that data – many tools that employers are using are trained on data about the employer's own workforce and prior hiring processes. But that data is itself reflective of existing institutional and systemic biases,' warned the American Civil Liberties Union.
In 2014, a team of engineers at Amazon began building an algorithm to review resumes and determine which applicants the tech giant should hire. The system was scrapped a year later because it discriminated against women applying for technical jobs.
Mobley said he received automated rejections again and again despite a finance degree from Morehouse College and experience since 2010 working in various financial, IT help desk and customer-service positions, sometimes in less than an hour. These systems are not 'race neutral, disability neutral or age neutral,' Mobley said in his complaint.
Another plaintiff, Jill Hughes, said she also received automated rejections for hundreds of roles, often within a few hours of applying.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
9 minutes ago
- Bloomberg
Nvidia, Samsung Plan Investments in Robotics Startup Skild AI
Samsung Electronics Co. and Nvidia Corp. will take minority stakes in Skild AI Inc. as they seek to bolster their work in the emerging consumer robotics industry. The South Korean tech leader is making a $10 million investment in Skild, which develops software for robots, according to people with knowledge of the matter. The Santa Clara, California chipmaker is putting in $25 million, said the people, who asked not to be identified discussing unannounced plans.
Yahoo
16 minutes ago
- Yahoo
Trump administration reviewing Biden-era submarine pact with Australia, UK
US President Donald Trump's administration has launched a formal review of former President Joe Biden's AUKUS defense pact with Australia and Britain to allow Australia to acquire nuclear-powered submarines, a US defense official said. Australia, which sees the submarines as critical to its own defense as tensions grow over China's expansive military buildup, said it remained committed to the project and looked forward to working closely with the US on the review. As well as causing alarm in Australia, the review could also throw a wrench in Britain's defense planning. AUKUS, worth hundreds of billions of dollars, is at the center of a planned expansion of Britain's submarine fleet. 'We are reviewing AUKUS as part of ensuring that this initiative of the previous administration is aligned with the President's America First agenda,' the US official said of the review, first reported by Financial Times. 'Any changes to the administration's approach for AUKUS will be communicated through official channels, when appropriate.' AUKUS was formed in 2021 to address worries about China's growing power. It envisages Australia acquiring up to five US Virginia-class submarines from 2032. Then, Britain and Australia would design and build a new class of submarine, with US assistance. The UK would take first delivery in the late 2030s, with delivery to Australia in the early 2040s. Before that, the US and Britain would start forward rotations of their submarines in 2027 out of an Australian naval base in Western Australia. Vocal skeptics among Trump's senior policy officials include Elbridge Colby, the Pentagon's top policy adviser, who cautioned last year that submarines were a scarce, critical commodity, and US industry could not produce enough to meet American demand. Submarines would be central to US military strategy in any confrontation with China centered in the First Island Chain, running from Japan through Taiwan, the Philippines and on to Borneo, enclosing China's coastal seas. 'My concern is why are we giving away this crown jewel asset when we most need it,' Colby said last year. Only six countries operate nuclear-powered submarines: the US, the UK, Russia, China, France and India. A spokesperson for Australia Defense Minister Richard Marles said the US had informed Australia and the UK of the review. 'AUKUS will grow both US and Australian defense industry as well as generating thousands of new manufacturing jobs,' the spokesperson said. A British government spokesperson called AUKUS 'one of the most strategically important partnerships in decades' that also produces 'jobs and economic growth in communities across all three nations.' 'It is understandable that a new administration would want to review its approach to such a major partnership, just as the UK did last year,' the official said, adding that Britain will 'continue to work closely with the US and Australia … to maximize the benefits and opportunities' of AUKUS. The White House did not immediately respond to a request for comment, but one official told Reuters the Trump administration 'is regularly reviewing foreign agreements to ensure they align with the American people's interests – especially those initiated under the failed Biden foreign policy agenda.' US Senator Tim Kaine, a Democrat on the Senate Armed Services Committee, said AUKUS was 'critical to ensuring a free and open Indo-Pacific' and the administration should work to strengthen it and the US submarine industrial base. 'Anything less would play directly into China's hand,' said Kaine, who represents Virginia, where US submarines are built. AUKUS is Australia's biggest-ever defense project, with Canberra committing to spend A$368 billion ($240 billion) over three decades to the program, which includes billions of dollars of investment in the U.S. production base. On Tuesday, Britain announced plans to invest billions of pounds to upgrade its submarine industry, including at BAE Systems in Barrow and Rolls-Royce Submarines in Derby, to boost submarine production as announced in Britain's Strategic Defence Review. Under this, it will build up to 12 next-generation attack submarines of the model intended to be jointly developed by the UK, US and Australia under AUKUS. In the US Congress on Tuesday, Defense Secretary Pete Hegseth said 'we're having honest conversations with our allies' and added in reference to Australia: 'We want to make sure those capabilities are part of how they use them with their submarines, but also how they integrate with us as allies.' Former Australian Prime Minister Malcolm Turnbull, who signed a previous agreement to acquire French submarines shelved in favor of AUKUS, told CNBC last week it was 'more likely than not that Australia will not end up with any submarines at all, but instead, simply provide a large base in Western Australia for the American Navy and maintenance facilities there.' AUKUS expert John Lee at Washington's conservative Hudson Institute think tank said the Pentagon review was aimed at determining whether it could afford to sell up to five submarines when it was not meeting its own production targets. Kathryn Paik, a Biden White House official now at Washington's Center for Strategic and International Studies, said providing submarines to Australia would not sacrifice US readiness but instead boost collective deterrence. 'This review most definitely makes our allies in Canberra and London concerned, and could cause them to doubt US reliability as an ally and partner,' she said.
Fast Company
23 minutes ago
- Fast Company
Enough hype about AI in health—let's talk about results
There's no shortage of big promises about AI in healthcare. The U.S. government announced a $500 billion Stargate initiative to fund AI infrastructure, while the UK government announced £82.6 million in research funding for three projects, two of which are using AI to tackle cancer and Alzheimer's disease. But ask any patient waiting for a diagnosis, or a clinician searching for certainty, and the real question cuts through all the noise: When will all the innovation deliver real impact where it matters most? We've entered an era where healthcare data is measured in exabytes—genomes, images, clinical notes, labs, and signals from every continent. At SOPHiA GENETICS, we've just achieved the milestone of analyzing 2 million patient profiles. It's a number that was unimaginable a decade ago. Yet the value of data isn't in volume. It's what you do with it. Insight matters only if it changes an outcome, shortens a diagnostic odyssey, or opens up a new chance for a patient. It's time to move from conversation to action. Too often, insights get trapped in institutional silos or left in endless pilot projects, just out of reach of the people who need them. 3 ways AI is already transforming medicine Today, technology can connect, for example, a patient in São Paulo with expertise in Seoul, uncovering patterns invisible to the human eye. Here are several ways AI is helping now. 1. Improving diagnostic accuracy: AI algorithms, particularly those based on deep learning, have demonstrated remarkable accuracy in diagnosing diseases from medical images and test results. These systems are trained on vast datasets, allowing them to recognize patterns and anomalies that might be missed by the human eye. For example, in dermatology, AI systems trained on images of skin lesions have shown the ability to detect skin cancers, such as melanoma, with high levels of precision. 2. Enhancing cancer prevention: AI techniques can be used to screen individuals for genomic markers and develop personalized cancer risk prediction scores. This proactive approach can help screen younger patients for genomic predispositions, empowering them to make informed prevention decisions and proactively monitor their health. 3. Tailoring treatments to genomic profiles: One of the most significant applications of AI is in the field of genomics. AI can analyze vast genomic datasets to identify mutations and variations that might influence an individual's response to certain treatments. For example, our SOPHiA DDM product can identify specific genomic markers that are susceptible to targeted cancer therapies, increasing the efficacy of the treatment and minimizing the risk of adverse reactions, for a more effective and safer treatment plan for patients. To scale up these AI applications there are many regulatory and compliance barriers to overcome. This requires investment in data security, creating clear guidelines, data security measures, and ensuring clinicians are fully trained. Our goal should be to create a regulatory environment that fosters innovation while safeguarding patient data and promoting public trust. We must democratize this powerful data to enable more physicians, practices, and hospitals to incorporate AI into daily clinical use so that a greater number of patients can access data-driven medicine, not just a select few. My message for governments investing in AI is clear: Balance investing in future AI tools with validating existing solutions that have already been proven to improve patient outcomes. Build the bridges that turn breakthroughs into benefits, so that data-driven medicine becomes a reality for every patient.
